- Satanists to use Hobby Lobby rule to skirt state abortion laws
- White House: No choice but to act now on climate change
- HHS: ‘Donut hole’ reforms saved Medicare enrollees $11.5 billion since 2010
- Boston-area tornado rips 100 homes: ‘Are we in Kansas?’
- Rush Limbaugh: ‘There is no journalism anymore’
- Scott Brown struggles for political traction in New Hampshire Senate race
- California’s Jerry Brown cites God, ‘religious call’ to embrace illegals
- Hamid Karzai’s cousin killed by suicide bomber at Eid al-Fitr party
- Obama thanks Muslims for ‘building the very fabric of our nation’
- Israel flattens home of top Hamas leader, takes out power plant
Panel to weigh Avandia’s safety
Question of the Day
A Food and Drug Administration advisory panel is scheduled to meet today to decide the fate of the diabetes drug Avandia.
The agency released a report last week showing that diabetes patients are at a higher risk for heart attacks when they combine Avandia with insulin. The report was released in advance of today's meeting of an independent advisory committee, made up of outside specialists, which will recommend whether Avandia should carry stronger warning labels or be banned from the U.S. market.
More than 6 million people worldwide have taken Avandia since GlaxoSmithKline introduced the drug in 1999, making it one of the most popular diabetes medications. Sales last year reached $3.4 billion.
The committee was called to meet after a report was released in May that said Avandia put diabetes patients at a 43 percent greater risk of heart attack.
The release of the agency's findings last week adds pressure to the advisory committee.
"From the get-go, FDA staffers saw trouble with Avandia. If the independent advisory committee members also see dangers, it will be important for diabetic patients to consider, and it will be further evidence that there are serious problems with FDA management style. A kick in the pants from the advisory committee could help force FDA management to pay more attention to their professional scientists," said Bill Vaughn, a policy analyst with Consumers Union.
The agency is not required to follow the recommendations of the advisory panel, but it rarely dismisses them.
Nancy Pekarek, a spokeswoman for GlaxoSmithKline, said the British company stands by the safety of its drug.
"Our view is that the sum of the data that we have available shows no increase in cardiovascular deaths and does not support a difference in heart-attack risk between Avandia and other common oral anti-diabetic medications," she said.
"We look forward to the opportunity to present our data [today]. An expert forum is the place to discuss this complex science," Ms. Pekarek added.
Regardless of the committee's decision, the agency's report is likely to spur civil litigation, observers say. Sales of Avandia dropped 31 percent to $226 million in the second quarter, the drug maker said last week, as safety concerns continue to emerge.
Mr. Vaughn's reference to FDA's "management style" stems from accusations by a former agency drug-safety supervisor who resigned after a recommendation to place a sterner warning, called a "black box," on the drug's label.
Rosemary Johann-Liang, deputy director of the division of drug-risk evaluation at the FDA, reportedly left the agency in frustration this year after being verbally criticized for signing off on the recommendation to place a heightened warning on Avandia for congestive heart failure.
Adding to the controversy surrounding Avandia, senators from the committee with partial oversight over the FDA released a letter claiming a second FDA official was reprimanded for expressing concern over the safety of the drug.
"A senior medical officer in the Office of New Drugs, who at one point was the primary reviewer for Avandia, told staff investigators that she or he was told to stop participation in the review of potential cardiovascular safety problems with Avandia," said Sens. Charles E. Grassley, Iowa Republican, and Max Baucus, Montana Democrat and chairman of the Senate Finance Committee.
The senators pointed out that the FDA medical officer reported to have been removed from reviewing Avandia "had the most experience with the drug class that includes Avandia."
Mr. Baucus and Mr. Grassley said they expect FDA Commissioner Andrew von Eschenbach to respond to their concerns by today, in time for the advisory committee meeting.
- GOP Senate candidate: Obama needs to visit Central America
- D.C. seeks to stay judge's order allowing gun owners to carry in public
- Hillary Clinton: Forget Obama, George W. Bush made her 'proud to be an American'
- Border surge puts Obama legacy on immigration at stake
- EPSTEIN: All IRS roads lead to the archivist
- Illegal immigrants demand representation in White House meetings
- Smugglers, rainstorm combine to poke holes in border fence
- Federal appeals court rules against Virginia's gay marriage ban
- PRUDEN: When the hangman botches the job
- Romney would win popular vote in rematch against Obama: CNN poll
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world
Fighting in Iraq